By Cole Bunn, Senior Research Analyst, LSN
Fundraising for a traditional medical device in the past several years has been tough, and it’s not getting any easier. New, groundbreaking therapeutic technologies and the explosion of health IT/digital health solutions has prevented a large portion of venture (and corporate) dollars from making their way into companies developing medical devices that require FDA approval, and don’t have some type of software or data component. In addition to “sexier” technologies wooing venture and strategic investors, some other difficult realities for medical devices include a poor exit environment, lower returns (as a sector) compared to biopharma and health IT and the fact that reimbursement still remains a formidable challenge. All of that aside, there is still a need in the healthcare arena for innovative medical devices.
In our second RESI conference of 2016, held at the TMCx accelerator, an experienced group of early-stage medical device investors discussed the sector’s current and future outlook, the Texas healthcare ecosystem and shared their insights on how entrepreneurs developing these products can successfully navigate the investment landscape. Moderated by Angela Shah, Editor, Xconomy, panelists include:
- Philip Sanger, Managing Partner, Texo Ventures
- Steve Banks, Venture Partner Emeritus, S3 Ventures
- James Eadie, Partner, Santé Ventures
- Andrew Offer, Chief Financial Officer & Managing Director, Scientific Health Development Partners
To hear directly from the investors, watch the RESI video recap here:
Next Phase Newsletter 
Leave a comment